Tissue-resident T cells, in situ immunity and transplantation

Immunological Reviews

Volumn 258, Issue 1, 2014, Pages 150-166

  Turner, Damian L ^a   Gordon, Claire L ^a,b   Farber, Donna L ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cell trafficking; Lung; Mucosa; T cells; Transplantation; Viral

Indexed keywords

CD44V ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR7; L SELECTIN; UVOMORULIN; IMMUNOSUPPRESSIVE AGENT;

ALLOIMMUNITY; ANTIGEN EXPRESSION; BK VIRUS INFECTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CROSS REACTION; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS INFECTION; GRAFT INFECTION; GRAFT REJECTION; HERPES SIMPLEX; IMMUNOMODULATION; INTESTINE GRAFT; KIDNEY ALLOGRAFT; LEUKOCYTE MIGRATION; LUNG TRANSPLANTATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MEMORY T LYMPHOCYTE; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE RESIDENT MEMORY T CELL; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TRANSPLANTATION; ALLOGRAFT; ANIMAL; COMMUNICABLE DISEASE; DRUG EFFECTS; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; ORGAN TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

ALLOGRAFTS; ANIMALS; COMMUNICABLE DISEASES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84893625865     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12149     Document Type: Review

References (208)

1. Kirk AD, Knechtle SJ, Larsen CP, Newell KA, Pearson TC. Miles to go. Am J Translpant 2011;11:1119-1120.
2. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-462.
3. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011;11:1226-1235.
4. Selvaggi G, et al. Intestinal and multivisceral transplantation at the University of Miami. Clin Transpl 2009;2009:211-217.
5. Kawai T, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358:353-361.
6. Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol 2013;31:137-161.
7. Masopust D, Picker LJ. Hidden memories: frontline memory T cells and early pathogen interception. J Immunol 2012;188:5811-5817.
8. Ganusov VV, De Boer RJ. Do most lymphocytes in humans really reside in the gut? Trends Immunol 2007;28:514-518.
9. Clark RA, Skin-resident T. cells: the ups and downs of on site immunity. J Invest Dermatol 2010;130:362-370.
10. Purwar R, Campbell J, Murphy G, Richards WG, Clark RA, Kupper TS. Resident memory T cells (T(RM)) are abundant in human lung: diversity, function, and antigen specificity. PLoS ONE 2011;6:e16245.
11. Bunders MJ, et al. Memory CD4(+)CCR5(+) T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1. Blood 2012;120:4383-4390.
12. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. Nat Immunol 2011;131:485-491.
13. Sallusto F, Langenkamp A, Geginat J, Lanzavecchia A. Functional subsets of memory T cells identified by CCR7 expression. Curr Top Microbiol Immunol 2000;251:167-171.
14. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-712.
15. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763.
16. Ahmadzadeh M, Hussain SF, Farber DL. Heterogeneity of the memory CD4 T cell response: persisting effectors and resting memory T cells. J Immunol 2001;166:926-935.
17. Wherry EJ, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003;4:225-234.
18. Bingaman AW, et al. Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in lymphoid and lung tissue. Eur J Immunol 2005;35:3173-3186.
19. Wang A, et al. The stoichiometric production of IL-2 and IFN-gamma mRNA defines memory T cells that can self-renew after adoptive transfer in humans. Sci Transl Med 2012;4:149ra120.
20. Pedron B, Guerin V, Cordeiro DJ, Masmoudi S, Dalle JH, Sterkers G. Development of cytomegalovirus and adenovirus-specific memory CD4 T-cell functions from birth to adulthood. Pediatr Res 2011;69:106-111.
21. Champagne P, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001;410:106-111.
22. Ellefsen K, Harari A, Champagne P, Bart PA, Sekaly RP, Pantaleo G. Distribution and functional analysis of memory antiviral CD8 T cell responses in HIV-1 and cytomegalovirus infections. Eur J Immunol 2002;32:3756-3764.
23. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001;291:2413-2417.
24. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001;410:101-105.
25. Gebhardt T, et al. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. Nature 2011;477:216-219.
26. Turner DL, et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol 2013; doi:10.1038/mi.2013.67. [Epub ahead of print].
27. Shinoda K, et al. Type II membrane protein CD69 regulates the formation of resting T-helper memory. Proc Natl Acad Sci USA 2012;109:7409-7414.
28. Strauch UG, et al. Integrin alpha E(CD103)beta 7 mediates adhesion to intestinal microvascular endothelial cell lines via an E-cadherin-independent interaction. J Immunol 2001;166:3506-3514.
29. Clark RA, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012;4:117ra117.
30. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat Med 2010;16:224-227.
31. Mackay LK, et al. Long-lived epithelial immunity by tissue-resident memory T (Trm) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci USA 2012;109:7037-7042.
32. Shin H, Iwasaki A. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 2012;491:463-467.
33. Klonowski KD, Williams KJ, Marzo AL, Blair DA, Lingenheld EG, Lefrancois L. Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity 2004;20:551-562.
34. Masopust D, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med 2010;207:553-564.
35. Masopust D, Vezys V, Wherry EJ, Barber DL, Ahmed R. Cutting edge: gut microenvironment promotes differentiation of a unique memory CD8 T cell population. J Immunol 2006;176:2079-2083.
36. Anderson KG, et al. Cutting edge: intravascular staining redefines lung CD8 T cell responses. J Immunol 2012;189:2702-2706.
37. Tse SW, Cockburn IA, Zhang H, Scott AL, Zavala F. Unique transcriptional profile of liver-resident memory CD8(+) T cells induced by immunization with malaria sporozoites. Genes Immun 2013;14:302-309.
38. Wakim LM, Woodward-Davis A, Bevan MJ. Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc Natl Acad Sci USA 2010;107:17872-17879.
39. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001;194:1541-1547.
40. Mora JR, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003;424:88-93.
41. Ito T, Carson W, Cavassani KA, Connett JM, Kunkel SL. CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res 2011;317:613-619.
42. Sathaliyawala T, et al. Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity 2013;38:187-197.
43. Clark RA, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol 2006;176:4431-4439.
44. Pauls K, et al. Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol 2001;117:569-575.
45. de Bree GJ, van Leeuwen EM, Out TA, Jansen HM, Jonkers RE, van Lier RA. Selective accumulation of differentiated CD8+ T cells specific for respiratory viruses in the human lung. J Exp Med 2005;202:1433-1442.
46. Zhu J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204:595-603.
47. Teijaro JR, Turner D, Pham Q, Wherry EJ, Lefrancois L, Farber DL. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol 2011;187:5510-5514.
48. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection generates non-migratory memory CD8+ Trm cells providing global skin immunity. Nature 2012;483:227-231.
49. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol 2009;10:524-530.
50. Wakim LM, Gebhardt T, Heath WR, Carbone FR. Cutting edge: local recall responses by memory T cells newly recruited to peripheral nonlymphoid tissues. J Immunol 2008;181:5837-5841.
51. Wakim LM, et al. The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J Immunol 2012;189:3462-3471.
52. Shoukry NH, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-1655.
53. Powrie F, Uhlig H. Animal models of intestinal inflammation: clues to the pathogenesis of inflammatory bowel disease. Novartis Found Symp 2004;263:164-174; discussion 174-168, 211-168.
54. Wucherpfennig KW. T cell receptor crossreactivity as a general property of T cell recognition. Mol Immunol 2004;40:1009-1017.
55. Valujskikh A, Memory T. cells in allograft rejection. Adv Exp Med Biol 2007;601:247-256.
56. Bingaman AW, Farber DL. Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant 2004;4:846-852.
57. Burrows SR, Khanna R, Burrows JM, Moss DJ. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med 1994;179:1155-1161.
58. D'Orsogna LJ, Roelen DL, Doxiadis II, Claas FH. Alloreactivity from human viral specific memory T-cells. Transpl Immunol 2010;23:149-155.
59. Macedo C, et al. Contribution of naive and memory T-cell populations to the human alloimmune response. Am J Transplant 2009;9:2057-2066.
60. Heeger PS, et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999;163:2267-2275.
61. Adams AB, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003;111:1887-1895.
62. Koyama I, et al. Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant 2007;7:1055-1061.
63. Nadazdin O, et al. Host alloreactive memory T cells influence tolerance to kidney allografts in nonhuman primates. Sci Transl Med 2011;3:86ra51.
64. Candon S, et al. Humoral and cellular immune responses after influenza vaccination in kidney transplant recipients. Am J Transplant 2009;9:2346-2354.
65. Zeevi A, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007;7:471-475.
66. Surh CD, Sprent J. Homeostasis of naive and memory T cells. Immunity 2008;29:848-862.
67. Hamilton SE, Wolkers MC, Schoenberger SP, Jameson SC. The generation of protective memory-like CD8+ T cells during homeostatic proliferation requires CD4+ T cells. Nat Immunol 2006;7:475-481.
68. Sener A, Tang AL, Farber DL. Memory T-cell predominance following T-cell depletional therapy derives from homeostatic expansion of naive T cells. Am J Transplant 2009;9:2615-2623.
69. Pearl JP, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-474.
70. Tang AL, Bingaman AW, Kadavil EA, Leeser DB, Farber DL. Generation and functional capacity of polyclonal alloantigen-specific memory CD4 T cells. Am J Transplant 2006;6:1275-1284.
71. Feng Y, Wang D, Yuan R, Parker CM, Farber DL, Hadley GA. CD103 expression is required for destruction of pancreatic islet allografts by CD8(+) T cells. J Exp Med 2002;196:877-886.
72. Wang D, et al. Regulation of CD103 expression by CD8+ T cells responding to renal allografts. J Immunol 2004;172:214-221.
73. Yuan R, El-Asady R, Liu K, Wang D, Drachenberg CB, Hadley GA. Critical role for CD103+CD8+ effectors in promoting tubular injury following allogeneic renal transplantation. J Immunol 2005;175:2868-2879.
74. Hadley GA, et al. Regulation of the epithelial cell-specific integrin, CD103, by human CD8+ cytolytic T lymphocytes. Transplantation 1999;67:1418-1425.
75. Smyth LJ, Kirby JA, Cunningham AC. Role of the mucosal integrin alpha(E)(CD103)beta(7) in tissue-restricted cytotoxicity. Clin Exp Immunol 2007;149:162-170.
76. El-Asady R, et al. TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease. J Exp Med 2005;201:1647-1657.
77. Schon MP, et al. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J Immunol 1999;162:6641-6649.
78. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011;140:502-508.
79. Norris S, et al. Resident human hepatic lymphocytes are phenotypically different from circulating lymphocytes. J Hepatol 1998;28:84-90.
80. Smith F, et al. Localization of T and B lymphocytes in histologically normal adult human donor liver. Hepatogastroenterolog 2003;50:1311-1315.
81. Alexander SI, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008;358:369-374.
82. Domiati-Saad R, Klintmalm GB, Netto G, Agura ED, Chinnakotla S, Smith DM. Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism. Am J Transplant 2005;5:2968-2973.
83. Richter N, Raddatz G, Graeter T, Schafers HJ, Schlitt HJ. Allogeneic lymphocyte chimerism after clinical lung transplantation. Transpl Immunol 1995;3:74-80.
84. Iwaki Y, et al. Replacement of donor lymphoid tissue in small-bowel transplants. Lancet 1991;337:818-819.
85. Rowntree LC, Bayliss J, Nguyen TH, Kotsimbos TC, Mifsud NA. Human leucocyte antigen-defined microchimerism early post-transplant does not predict for stable lung allograft function. Clin Exp Immunol 2013;172:483-489.
86. Paantjens AW, et al. Chimerism of dendritic cell subsets in peripheral blood after lung transplantation. J Heart Lung Transplant 2011;30:691-697.
87. Bittmann I, et al. Cellular chimerism of the lung after transplantation. An interphase cytogenetic study. Am J Clin Pathol 2001;115:525-533.
88. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
89. Shulman Z, et al. Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin. Immunity 2009;30:384-396.
90. Strom TB. Transplant rejection and paradigms lost. J Clin Invest 2013;123:2360-2362.
91. Walch JM, et al. Cognate antigen directs CD8+ T cell migration to vascularized transplants. J Clin Invest 2013;123:2663-2671.
92. Panzer U, et al. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 2004;78:1341-1350.
93. Hancock WW, et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000;192:1515-1520.
94. Hancock WW, Gao W, Csizmadia V, Faia KL, Shemmeri N, Luster AD. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001;193:975-980.
95. Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplantation 2002;74:149-155.
96. Hancock WW. Chemokines and transplant immunobiology. J Am Soc Nephrol 2002;13:821-824.
97. Nelson PJ, Krensky AM. Chemokines, chemokine receptors, and allograft rejection. Immunity 2001;14:377-386.
98. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60-66.
99. Savinov AY, Wong FS, Stonebraker AC, Chervonsky AV. Presentation of antigen by endothelial cells and chemoattraction are required for homing of insulin-specific CD8+ T cells. J Exp Med 2003;197:643-656.
100. Hunninghake GW, Gadek JE, Kawanami O, Ferrans VJ, Crystal RG. Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol 1979;97:149-206.
101. Gryzan S, Paradis IL, Hardesty RL, Griffith BP, Dauber JH. Bronchoalveolar lavage in heart-lung transplantation. J Heart Transplant 1985;4:414-416.
102. de Blic J, et al. Rejection in lung transplantation-an immunohistochemical study of transbronchial biopsies. Transplantation 1992;54:639-644.
103. Tiroke AH, Bewig B, Haverich A. Bronchoalveolar lavage in lung transplantation. State of the art. Clin Transplant 1999;13:131-157.
104. Zheng L, et al. Longitudinal comparisons of lymphocytes and subtypes between airway wall and bronchoalveolar lavage after human lung transplantation. Transplantation 2005;80:185-192.
105. Pipeling MR, et al. Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection. J Immunol 2008;181:546-556.
106. Starzl TE, et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 1993;17:1127-1152.
107. Sirinek LP, O'Dorisio MS, Dunaway DJ. Accumulation of donor-specific cytotoxic T cells in intestinal lymphoid tissues following intestinal transplantation. J Clin Immunol 1995;15:258-265.
108. Abu-Elmagd KM, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transplant Int 2009;22:96-109.
109. Shen B, Yu H, Hao X, Qu L, Cai X, Li N. Impact of antimouse CD52 monoclonal antibody on graft's gammadelta intraepithelial lymphocytes after orthotopic small bowel transplantation in mice. Transplantation 2013;95:663-670.
110. Gebhardt T, Mackay LK. Local immunity by tissue-resident CD8(+) memory T cells. Front Immunol 2012;3:340.
111. Zuckerman RA, Limaye AP. Varicella zoster virus (VZV) and herpes simplex virus (HSV) in solid organ transplant patients. Am J Transplant 2013;13(Suppl):55-66; quiz 66.
112. Other herpesviruses: HHV-6, HHV-7, HHV-8, HSV-1 and -2, VZV. Am J Transplant 2004;4(Suppl):66-71.
113. Wakim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. Science 2008;319:198-202.
114. Zhu J, et al. Immune surveillance by CD8alphaalpha skin-resident T cells in human herpes virus infection. Nature 2013;497:494-497.
115. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010;20:202-213.
116. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant 2013;13(Suppl):24-40; quiz 40.
117. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 2008;41:180-185.
118. Koffron AJ, et al. Cellular localization of latent murine cytomegalovirus. J Virol 1998;72:95-103.
119. Seckert CK, et al. Liver sinusoidal endothelial cells are a site of murine cytomegalovirus latency and reactivation. J Virol 2009;83:8869-8884.
120. Torti N, Walton SM, Brocker T, Rulicke T, Oxenius A. Non-hematopoietic cells in lymph nodes drive memory CD8 T cell inflation during murine cytomegalovirus infection. PLoS Pathog 2011;7:e1002313.
121. Sierro S, Rothkopf R, Klenerman P. Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. Eur J Immunol 2005;35:1113-1123.
122. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol 2006;177:450-458.
123. Munks MW, et al. Genome-wide analysis reveals a highly diverse CD8 T cell response to murine cytomegalovirus. J Immunol 2006;176:3760-3766.
124. Torti N, Oxenius A. T cell memory in the context of persistent herpes viral infections. Viruses 2012;4:1116-1143.
125. Jonjic S, Mutter W, Weiland F, Reddehase MJ, Koszinowski UH. Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med 1989;169:1199-1212.
126. Letsch A, et al. CMV-specific central memory T cells reside in bone marrow. Eur J Immunol 2007;37:3063-3068.
127. Elkington R, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003;77:5226-5240.
128. Sylwester AW, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005;202:673-685.
129. Hadrup SR, et al. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J Immunol 2006;176:2645-2653.
130. Vescovini R, et al. Massive load of functional effector CD4+ and CD8+ T cells against cytomegalovirus in very old subjects. J Immunol 2007;179:4283-4291.
131. Kern F, et al. Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol 1999;29:2908-2915.
132. Scheinberg P, et al. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood 2009;114:5071-5080.
133. van de Berg PJ, van Stijn A, Ten Berge IJ, van Lier RA. A fingerprint left by cytomegalovirus infection in the human T cell compartment. J Clin Virol 2008;41:213-217.
134. Appay V, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002;8:379-385.
135. Wills MR, Okecha G, Weekes MP, Gandhi MK, Sissons PJ, Carmichael AJ. Identification of naive or antigen-experienced human CD8(+) T cells by expression of costimulation and chemokine receptors: analysis of the human cytomegalovirus-specific CD8(+) T cell response. J Immunol 2002;168:5455-5464.
136. Sissons JG, Bain M, Wills MR. Latency and reactivation of human cytomegalovirus. J Infect 2002;44:73-77.
137. Gattinoni L, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17:1290-1297.
138. Makedonas G, et al. Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog 2010;6:e1000798.
139. Luo XH, Huang XJ, Liu KY, Xu LP, Liu DH. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2010;16:994-1004.
140. Bitmansour AD, Douek DC, Maino VC, Picker LJ. Direct ex vivo analysis of human CD4(+) memory T cell activation requirements at the single clonotype level. J Immunol 2002;169:1207-1218.
141. Rentenaar RJ, et al. Development of virus-specific CD4(+) T cells during primary cytomegalovirus infection. J Clin Invest 2000;105:541-548.
142. Elkington R, et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur J Immunol 2004;34:3216-3226.
143. Weekes MP, Wills MR, Sissons JG, Carmichael AJ. Long-term stable expanded human CD4+ T cell clones specific for human cytomegalovirus are distributed in both CD45RAhigh and CD45ROhigh populations. J Immunol 2004;173:5843-5851.
144. van Leeuwen EM, Remmerswaal EB, Heemskerk MH, ten Berge IJ, van Lier RA. Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood 2006;108:3121-3127.
145. Egli A, Kumar D, Broscheit C, O'Shea D, Humar A. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. Transplantation 2013;95:448-455.
146. Dolcetti R, Masucci MG. Epstein-Barr virus: induction and control of cell transformation. J Cell Physiol 2003;196:207-218.
147. Pai S, Khanna R. Role of LMP1 in immune control of EBV infection. Semin Cancer Biol 2001;11:455-460.
148. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Autoimmun Rev 2007;7:96-101.
149. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-230.
150. Dotti G, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation 2002;74:1095-1102.
151. Ghobrial IM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005;46:191-196.
152. Caillard S, et al. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score. J Clin Oncol 2013;31:1302-1309.
153. Murukesan V, Mukherjee S. Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens. Drugs 2012;72:1631-1643.
154. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011;86:206-209.
155. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995;103:748-755.
156. Evens AM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038-1046.
157. Leblond V, et al. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2001;19:772-778.
158. Maecker B, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007;25:4902-4908.
159. Richendollar BG, et al. Predictors of outcome in post-transplant lymphoproliferative disorder: an evaluation of tumor infiltrating lymphocytes in the context of clinical factors. Leuk Lymphoma 2009;50:2005-2012.
160. Bollard CM. Improving T-cell therapy for epstein-barr virus lymphoproliferative disorders. J Clin Oncol 2013;31:5-7.
161. Vaglio A, et al. EBV-associated leukoencephalopathy with late onset of central nervous system lymphoma in a kidney transplant recipient. Am J Transplant 2010;10:947-951.
162. Terasawa T, et al. Failure to detect Epstein-Barr virus (EBV) DNA in plasma by real-time PCR in a case of EBV-associated posttransplantation lymphoproliferative disorder confined to the central nervous system. Int J Hematol 2002;75:416-420.
163. Kittan NA, et al. Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges. Transpl Infect Dis 2011;13:524-530.
164. Shimizu H, et al. Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Int J Hematol 2011;94:495-498.
165. Bonney DK, et al. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 2012;58:459-461.
166. Bossolasco S, et al. Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. J Neurovirol 2002;8:432-438.
167. Boersma MN, van der Zanden A, Laverman GD, Sanders JS, de Vries PA. Epstein-Barr virus-positive post-transplant lymphoproliferative disorder of the central nervous system, after renal transplantation with a discrepancy in viral load between peripheral blood and cerebrospinal fluid. Transplant Int 2012;25:e113-e116.
168. Durrbach A, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010;10:547-557.
169. Ndejembi MP, et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006;177:7698-7706.
170. Lo DJ, et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 2011;11:22-33.
171. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer 2005;104:1661-1667.
172. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep 2010;12:383-394.
173. Abdallah KO, Prak ET. B cell monitoring of transplant patients treated with anti-CD20. Clin Transpl 2006;2006:427-437.
174. Miloh T, Arnon R, Roman E, Hurlet A, Kerkar N, Wistinghausen B. Autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura in pediatric solid organ transplant recipients, report of five cases and review of the literature. Pediatr Transplant 2011;15:870-878.
175. Ziring D, et al. Infectious enteritis after intestinal transplantation: incidence, timing, and outcome. Transplantation 2005;79:702-709.
176. Adeyi OA, Costa G, Abu-Elmagd KM, Wu T. Rotavirus infection in adult small intestine allografts: a clinicopathological study of a cohort of 23 patients. Am J Transplant 2010;10:2683-2689.
177. Morotti RA, et al. Calicivirus infection in pediatric small intestine transplant recipients: pathological considerations. Hum Pathol 2004;35:1236-1240.
178. Kaufman SS, et al. Calicivirus enteritis in an intestinal transplant recipient. Am J Transplant 2003;3:764-768.
179. Kaufman SS, et al. Characteristics of human calicivirus enteritis in intestinal transplant recipients. J Ped Gastroenterol Nutr 2005;40:328-333.
180. Eisengart LJ, Chou PM, Iyer K, Cohran V, Rajaram V. Rotavirus infection in small bowel transplant: a histologic comparison with acute cellular rejection. Ped Dev Pathol 2009;12:85-88.
181. Loinaz C, et al. Bacterial infections after intestine and multivisceral transplantation. Transplant Proc 2003;35:1929-1930.
182. Cordero E, Manuel O. Influenza vaccination in solid-organ transplant recipients. Curr Opin Organ Transplant 2012;17:601-608.
183. Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 2009;87:621-630.
184. Smith JM, Dharnidharka VR, Talley L, Martz K, McDonald RA. BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2007;2:1037-1042.
185. Goudsmit J, Wertheim-van Dillen P, van Strien A, van der Noordaa J. The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol 1982;10:91-99.
186. Chatterjee M, Weyandt TB, Frisque RJ. Identification of archetype and rearranged forms of BK virus in leukocytes from healthy individuals. J Med Virol 2000;60:353-362.
187. Bennett SM, Broekema NM, Imperiale MJ. BK polyomavirus: emerging pathogen. Microbes Infect 2012;14:672-683.
188. Zhou W, et al. Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol 2007;20:379-388.
189. Ramaswami B, et al. The polyomavirus BK large T-antigen-derived peptide elicits an HLA-DR promiscuous and polyfunctional CD4+ T-cell response. Clin Vaccine Immunol 2011;18:815-824.
190. Provenzano M, et al. Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors. J Transl Med 2006;4:47.
191. Binggeli S, et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 2007;7:1131-1139.
192. Schachtner T, et al. BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant 2011;11:2443-2452.
193. Comoli P, Hirsch HH, Ginevri F. Cellular immune responses to BK virus. Curr Opin Organ Transplant 2008;13:569-574.
194. Hammer MH, et al. HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant 2006;6:625-631.
195. Babel N, Volk HD, Reinke P. BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nat Rev Nephrol 2011;7:399-406.
196. Han Lee ED, et al. A mouse model for polyomavirus-associated nephropathy of kidney transplants. Am J Transplant 2006;6:913-922.
197. Luo C, Hirsch HH, Kant J, Randhawa P. VP-1 quasispecies in human infection with polyomavirus BK. J Med Virol 2012;84:152-161.
198. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002;14:569-575.
199. Niven RW. Toward managing chronic rejection after lung transplant: the fate and effects of inhaled cyclosporine in a complex environment. Adv Drug Deliv Rev 2011;63:88-109.
200. Pittet LF, Posfay-Barbe KM. Immunization in transplantation: review of the recent literature. Curr Opin Organ Transplant 2013;18:543-548.
201. Le Corre N, et al. Effect of two injections of non-adjuvanted influenza A H1N1pdm2009 vaccine in renal transplant recipients: INSERM C09-32 TRANSFLUVAC trial. Vaccine 2012;30:7522-7528.
202. Shin H, Iwasaki A. Tissue-resident memory T cells. Immunol Rev 2013;255:165-181.
203. Crespo G, et al. Viral hepatitis in liver transplantation. Gastroenterology 2012;142:1373-1383.
204. Martin ST, Torabi MJ, Gabardi S. Influenza in solid organ transplant recipients. Ann Pharmacother 2012;46:255-264.
205. Herati RS, Blumberg EA. Losing ground: multidrug-resistant bacteria in solid-organ transplantation. Curr Opin Infect Dis 2012;25:445-449.
206. Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008;13:592-600.
207. Singh N, Forrest G. Cryptococcosis in solid organ transplant recipients. Am J Transplant 2009;9(Supp 4):S192-S198.
208. Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. Semin Respir Crit Care Med 2010;31:222-233.